GlassScriptPhysician profile
Henry T Wynn
NPI 1053353805
$5,472.31
in general payments reported to CMS, 2019-2025
30 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $912 · 2022: $1,779 · 2023: $1,443 · 2024: $811 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,781.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $843.55 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $547.31 | 2021-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $463.94 | 2021-2025 | |
| Amgen INC. | $400.07 | 2022-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $395.76 | 2022-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $381.53 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.29 | 2021-2025 | Jardiance |
| Pfizer INC. | $241.17 | 2022-2025 | |
| Esperion Therapeutics, INC. | $239.14 | 2021-2024 | Nexletol |
| Kestra Medical Technology Services, INC. | $194.30 | 2023-2025 | Assure Wcd |
| Scpharmaceuticals INC. | $189.00 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $157.48 | 2021-2024 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $146.78 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $120.43 | 2023 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $108.24 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $87.23 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals, LTD. | $71.03 | 2022-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $70.14 | 2025 | Amvuttra |
| Kowa Pharmaceuticals America, INC. | $65.00 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $64.77 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $57.48 | 2023-2024 | Evkeeza |
| Tactile Systems Technology INC | $54.05 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Baxter Healthcare | $40.77 | 2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Irhythm Technologies, INC. | $38.52 | 2022-2023 | Zio Xt Patch |
| Actelion Pharmaceuticals US, INC. | $32.46 | 2022 | |
| Chiesi USA, INC. | $23.07 | 2021 | |
| Cardiva Medical, INC. | $22.45 | 2023 | Cardiva Vascade 6/7f Vcs |
| Boston Scientific Corporation | $16.14 | 2022 | |
| Lilly USA, LLC | $15.67 | 2025 | Mounjaro, Zepbound |
| Lantheus Medical Imaging, INC. | $14.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Wynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.